Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
| Website: | www.auriniapharma.com |
| Email: | ir@auriniapharma.com |
| Main Phone: | +1 250 744-2487 |
| Address: | 4464 Markham Street |
| Address 2: | Suite 1203 |
| State: | BC |
| City / Town: | Victoria |
| Country: | CAN |
| Postal Code: | V8Z 7X8 |
| Exchange: | TSX |
| CEO: | Richard M. Glickman |
| Employees: | 33 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
| Last Price 7.59 | Change $ 0.36 | Change % 4.98 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask N/A | Ask Size 0.00 |
| Open 7.27 | High 7.64 | Low 7.27 | Prev Close 7.23 |
| Last Trade | Volume 3,200 | 52 Wk Hi 9.50 | 52 Wk Low 5.70 |
| Market Cap 647.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 85,320,467.00 | EPS (TTM) -0.71 | PE Ratio N/A | Exchange TSX |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 20.94 | 20.94 | 20.94 | 20.94 |
| Low Target Price Estimate | 12.8 | 12.8 | 12.8 | 12.8 |
| Mean Target Price Estimate | 16.27 | 16.27 | 16.27 | 16.27 |
| Standard Deviation | 3.2 | 3.2 | 3.2 | 3.2 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 06/25/18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.41 | 1.41 | 1.41 | 1.41 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
